The conjugacy of the use of synbiotic Maxilac® with the severity and duration of the course of COVID-19 in outpatient treatment | Soldatova | Experimental and Clinical Gastroenterology

Experimental and Clinical Gastroenterology
Èksperimentalʹnaâ i kliničeskaâ gastroènterologiâ

ISSN 1682-8658 (Print)

eng | рус

Preview

Experimental and Clinical Gastroenterology

Advanced search

Archives

Download this PDF file

For citations:

Soldatova O.V., Goryanskaya I.Ya., Zaharyan E.A., Ivanchenko V.S. The conjugacy of the use of synbiotic Maxilac® with the severity and duration of the course of COVID-19 in outpatient treatment. Experimental and Clinical Gastroenterology. 2022;(11):86-93. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-207-11-86-93

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1682-8658 (Print)

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles

Editor-in-Chief

Leonid Lazebnik

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

O. V. Soldatova
Institute “Medical Academy named after S. I. Georgievsky” FGАOU VO “СFU named after V. I. Vernadsky”
Russian Federation

I. Ya. Goryanskaya
Institute “Medical Academy named after S. I. Georgievsky” FGАOU VO “СFU named after V. I. Vernadsky”
Russian Federation

E. A. Zaharyan
Institute “Medical Academy named after S. I. Georgievsky” FGАOU VO “СFU named after V. I. Vernadsky”
Russian Federation

V. S. Ivanchenko
Institute “Medical Academy named after S. I. Georgievsky” FGАOU VO “СFU named after V. I. Vernadsky”
Russian Federation

Notifications